Table of Contents Author Guidelines Submit a Manuscript
Experimental Diabetes Research
Volume 2012, Article ID 905683, 7 pages
http://dx.doi.org/10.1155/2012/905683
Research Article

Effects of Rosiglitazone with Insulin Combination Therapy on Oxidative Stress and Lipid Profile in Left Ventricular Muscles of Diabetic Rats

1Department of Biophysics, Faculty of Medicine, Yüzüncü Yıl University, 65100 Van, Turkey
2Department of Biochemistry, Faculty of Medicine, Mersin University, 33343 Mersin, Turkey
3Department of Biophysics, Faculty of Medicine, Çukurova University, 01330 Adana, Turkey

Received 13 February 2012; Accepted 1 May 2012

Academic Editor: Pietro Galassetti

Copyright © 2012 Servet Kavak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Ceriello and E. Motz, “Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 5, pp. 816–823, 2004. View at Publisher · View at Google Scholar · View at Scopus
  2. D. Aronson and E. J. Rayfield, “How hyperglycemia promotes atherosclerosis: molecular mechanisms,” Cardiovascular Diabetology, vol. 1, article 1, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. N. Houstis, E. D. Rosen, and E. S. Lander, “Reactive oxygen species have a causal role in multiple forms of insulin resistance,” Nature, vol. 440, no. 7086, pp. 944–948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. A. J. Vidal-Puig, R. V. Considine, M. Jimenez-Linan et al., “Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids,” Journal of Clinical Investigation, vol. 99, no. 10, pp. 2416–2422, 1997. View at Google Scholar · View at Scopus
  5. H. Yki-Jarvinen, “Thiazolidinedione,” The New England Journal of Medicine, vol. 351, pp. 1106–1118, 2004. View at Publisher · View at Google Scholar
  6. N. Houstis, E. D. Rosen, and E. S. Lander, “Reactive oxygen species have a causal role in multiple forms of insulin resistance,” Nature, vol. 440, no. 7086, pp. 944–948, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. P. D. Miles, K. Higo, O. M. Romeo, M. K. Lee, K. Rafaat, and J. M. Olefsky, “Troglitazone prevents hyperglycemia-induced but not glucosamine-induced insulin resistance,” Diabetes, vol. 47, no. 3, pp. 395–400, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. I. Barroso, M. Gurnell, V. E. Crowley et al., “Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, no. 6764, pp. 880–883, 1999. View at Publisher · View at Google Scholar · View at Scopus
  10. V. Bonnevie-Nielsen, M. W. Steffes, and A. Lernmark, “A major loss in islet mass and b-cell function precedes hyperglycemia in mice given multiple low doses of streptozotocin,” Diabetes, vol. 30, no. 5, pp. 424–429, 1981. View at Google Scholar · View at Scopus
  11. B. Ramesh and K. V. Pugalendi, “Influence of umbelliferone on membrane-bound ATPases in streptozotocin-induced diabetic rats,” Pharmacological Reports, vol. 59, no. 3, pp. 339–348, 2007. View at Google Scholar · View at Scopus
  12. S. P. Sawant, A. V. Dnyanmote, K. Shankar, P. B. Limaye, J. R. Latendresse, and H. M. Mehendale, “Potentiation of carbon tetrachloride hepatotoxicity and lethality in type 2 diabetic rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 308, no. 2, pp. 694–704, 2004. View at Publisher · View at Google Scholar · View at Scopus
  13. W. T. Friedewald, R. I. Levy, and D. S. Fredrickson, “Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge,” Clinical Chemistry, vol. 18, no. 6, pp. 499–502, 1972. View at Google Scholar · View at Scopus
  14. K. Yagi, “Lipid peroxides and related radicals in clinical medicine,” in Free Radicals in Diagnostic Medicine, D. Armstrong, Ed., pp. 1–15, Plenum, New York, NY, USA, 1994. View at Google Scholar
  15. A. Ünlü, N. Türkozkan, B. Çimen, U. Karabýçak, and H. Yaman, “The effects of Escherichia coli-derived lipopolysaccharides on plasma levels of malondialdehyde and 3-nitrotyrosine,” Clinical Chemistry and Laboratory Medicine, vol. 39, pp. 491–493, 2001. View at Publisher · View at Google Scholar
  16. D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kavak, L. Ayaz, M. Emre, T. Inal, L. Tamer, and I. Günay, “The effects of rosiglitazone on oxidative stress and lipid profile in left ventricular muscles of diabetic rats,” Cell Biochemistry and Function, vol. 26, no. 4, pp. 478–485, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. B. M. Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar · View at Scopus
  20. R. Kahn, “Consensus development conference on insulin resistance: 5-6 November 1997,” Diabetes Care, vol. 21, no. 2, pp. 310–314, 1998. View at Google Scholar · View at Scopus
  21. A. C. Calkin, J. M. Forbes, C. M. Smith et al., “Rosiglitazone attenuates atherosclerosis in a model of insulin insufficiency independent of its metabolic effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1903–1909, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Iozzo, K. Hallsten, V. Oikonen et al., “Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes,” Diabetes Care, vol. 26, no. 7, pp. 2069–2074, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. J. M. Malinowski and S. Bolesta, “Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review,” Clinical Therapeutics, vol. 22, no. 10, pp. 1151–1168, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Chaudhry, N. N. Ghosh, K. Roy, and R. Chandra, “Antihyperglycemic effect of a new thiazolidinedione analogue and its role in ameliorating oxidative stress in alloxan-induced diabetic rats,” Life Sciences, vol. 80, no. 12, pp. 1135–1142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. M. R. Taskinen, “Insulin resistance and lipoprotein metabolism,” Current Opinion in Lipidology, vol. 6, no. 3, pp. 153–160, 1995. View at Google Scholar · View at Scopus
  26. G. M. Reaven, Y. D. Chen, J. Jeppesen, P. Maheux, and R. M. Krauss, “Insulin resistance and hyperinsulinemia in individuals with small, dense, low density lipoprotein particles,” Journal of Clinical Investigation, vol. 92, no. 1, pp. 141–146, 1993. View at Google Scholar · View at Scopus
  27. B. Staels and J. Auwers, “Role of PPAR in the pharmacological regulation of lipoprotein metabolism by fibrates and thiazolidinediones,” Current Pharmaceutical Design, vol. 3, no. 1, pp. 1–14, 1997. View at Google Scholar · View at Scopus
  28. W. Zhao-hui, L. Feng, and L. Xiao-mei, “Effect of PPARγ agonist rosiglitazone on regression of the atherosclerotic plaques in rabbits,” Yao Xue Xue Bao, vol. 40, no. 11, pp. 1051–1053, 2005. View at Google Scholar · View at Scopus
  29. Z. Levi, A. Shaish, N. Yacov et al., “Rosiglitazone (PPARγ-agonist) attenuates atherogenesis with no effect on hyperglycaemia in a combined diabetes-atherosclerosis mouse model,” Diabetes, Obesity and Metabolism, vol. 5, no. 1, pp. 45–50, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Tao, H. R. Liu, E. Gao et al., “Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-γ agonist in hypercholesterolemia,” Circulation, vol. 108, no. 22, pp. 2805–2811, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. P. J. Boyle, A. B. King, L. Olansky et al., “Effects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical records,” Clinical Therapeutics, vol. 24, no. 3, pp. 378–396, 2002. View at Publisher · View at Google Scholar · View at Scopus
  32. A. B. Mayerson, R. S. Hundal, S. Dufour et al., “The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes,” Diabetes, vol. 51, no. 3, pp. 797–802, 2002. View at Google Scholar · View at Scopus
  33. Z. Bagi, A. Koller, and G. Kaley, “PPARγ activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with Type 2 diabetes,” American Journal of Physiology, vol. 286, no. 2, pp. H742–H748, 2004. View at Google Scholar · View at Scopus
  34. R. Radi, A. Denicola, B. Alvarez, G. Ferrer-Sueta, and H. Rubbo, “The biological chemistry of peroxynitrite,” in Introduction and Overview, J. L. Ignarro, Ed., pp. 57–82, Academic Press, 2000. View at Google Scholar
  35. C. D. Filippo, S. Cuzzocrea, F. Rossi, R. Marfella, and M. D'Amico, “Oxidative stress as the leading cause of acute myocardial infarction in diabetics,” Cardiovascular Drug Reviews, vol. 24, no. 2, pp. 77–87, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation,” Nature, vol. 391, no. 6662, pp. 79–82, 1998. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Shiojiri, K. Wada, A. Nakajima et al., “PPARγ ligands inhibit nitrotyrosine formation and inflammatory mediator expressions in adjuvant-induced rheumatoid arthritis mice,” European Journal of Pharmacology, vol. 448, no. 2-3, pp. 231–238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Hwang, D. J. Kleinhenz, B. Lassègue, K. K. Griendling, S. Dikalov, and C. M. Hart, “Peroxisome proliferator-activated receptor-γ ligands regulate endothelial membrane superoxide production,” American Journal of Physiology, vol. 288, no. 4, pp. C899–C905, 2005. View at Publisher · View at Google Scholar · View at Scopus
  39. D. S. Calnek, L. Mazzella, S. Roser, J. Roman, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands increase release of nitric oxide from endothelial cells,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 1, pp. 52–57, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. J. A. Polikandriotis, L. J. Mazzella, H. L. Rupnow, and C. M. Hart, “Peroxisome proliferator-activated receptor γ ligands stimulate endothelial nitric oxide production through distinct peroxisome proliferator-activated receptor γ-dependent mechanisms,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 9, pp. 1810–1816, 2005. View at Publisher · View at Google Scholar · View at Scopus